Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck…